Evidence map›Paper›PMID 39918606›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2025

Rebalancing Immune Interactions within the Brain-Spleen Axis Mitigates Neuroinflammation in an Aging Mouse Model of Alzheimer's Disease.

Anna Flavia Cantone, Chiara Burgaletto, Giulia Di Benedetto, Gabriella Gaudio, Cesarina Giallongo, Rosario Caltabiano, Giuseppe Broggi, Carlo Maria Bellanca, Giuseppina Cantarella, Renato Bernardini

Abstract read
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. The spleen-brain axis in Alzheimer's disease and related dementias: Integrating immune and metabolic regulation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anna Flavia CantoneDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Chiara BurgalettoDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Giulia Di BenedettoDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy. giulia.dibenedetto@unict.it.
Gabriella GaudioDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Cesarina GiallongoDepartment of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Division of Hematology, University of Catania, Catania, Italy.
Rosario CaltabianoDepartment of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, Catania, Italy.
Giuseppe BroggiDepartment of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, Catania, Italy.
Carlo Maria BellancaDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Giuseppina CantarellaDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Renato BernardiniDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.

Funding

Regione Sardegna, legge regionale 7 agosto 2007 n.7- promozione della ricerca scientifica e dell'innovazione tecnologica in Sardegna PNRR MAD-2022-12375802
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common cause of dementia worldwide, characterized by accumulation of amyloid-β protein and hyperphosphorylated tau protein in the brain. Neuroinflammation, resulting from chronic activation of brain-resident innate immune cells as well as enhanced peripheral leukocyte access across the blood-brain barrier, crucially affects AD progression. In this context, TNFSF10, a cytokine substantially expressed in the AD brain, has been shown to modulate both the innate and the adaptive branches of the immune response in AD-related neuroinflammation. In this study, we explored whether a TNFSF10-neutralizing treatment could represent a tool to re-balance the overall overshooting inflammatory response in a mouse model of AD. Specifically, 3xTg-AD mice were treated sub-chronically with an anti-TNFSF10 monoclonal antibody for three months, and were then sacrificed at 15 months. TNFSF10 neutralization reduced the expression of the inflammatory marker CD86, inversely related to levels of the anti-inflammatory marker CD206 in the brain of 3xTg-AD mice, suggesting a switch of microglia towards a neuroprotective phenotype. Similar results were observed in the splenic macrophage population. Moreover, flow cytometry revealed a significant decrease of CD4

Indexed as

AgingAlzheimer DiseaseBrainNeuroinflammatory DiseasesSpleenAnimalsDisease Models, AnimalMaleMiceMice, TransgenicCNS-resident innate immunocytesCytokinesImmune exhaustionImmune responseNeuroinflammationSplenocytes

Identifiers

PMID39918606
PMCPMC11805801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.